Stephen M. Stahl: Mechanism of action of pimavanserin in Parkinson’s disease psychosis: targeting serotonin 5HT2A and 5HT2C receptors. In: CNS Spectrums. Band21, Nr.4, August 2016, S.271–275, doi:10.1017/S1092852916000407.
Joseph H Friedman: Pimavanserin for the treatment of Parkinson's disease psychosis. In: Expert Opinion on Pharmacotherapy. Band14, Nr.14, Oktober 2013, S.1969–1975, doi:10.1517/14656566.2013.819345.
David Nutt, Stephen Stahl, Pierre Blier, Filippo Drago, Joseph Zohar: Inverse agonists – What do they mean for psychiatry? In: European Neuropsychopharmacology. Band27, Nr.1, Januar 2017, S.87–90, doi:10.1016/j.euroneuro.2016.11.013.
Javier González-Maeso, Noelia V. Weisstaub, Mingming Zhou, Pokman Chan, Lidija Ivic: Hallucinogens Recruit Specific Cortical 5-HT2A Receptor-Mediated Signaling Pathways to Affect Behavior. In: Neuron. Band53, Nr.3, Februar 2007, S.439–452, doi:10.1016/j.neuron.2007.01.008.
Luis R. Gardell, Kimberly E. Vanover, Linda Pounds, Robert W. Johnson, Richard Barido: ACP-103, a 5-Hydroxytryptamine 2A Receptor Inverse Agonist, Improves the Antipsychotic Efficacy and Side-Effect Profile of Haloperidol and Risperidone in Experimental Models. In: Journal of Pharmacology and Experimental Therapeutics. Band322, Nr.2, August 2007, S.862–870, doi:10.1124/jpet.107.121715.
K Vanover, A Betz, S Weber, F Bibbiani, A Kielaite: A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model. In: Pharmacology Biochemistry and Behavior. Band90, Nr.4, Oktober 2008, S.540–544, doi:10.1016/j.pbb.2008.04.010, PMID 18534670, PMC 2806670 (freier Volltext).
Atheir Abbas, Bryan L. Roth: Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders. In: Expert Opinion on Pharmacotherapy. Band9, Nr.18, Dezember 2008, S.3251–3259, doi:10.1517/14656560802532707, PMID 19040345.
Herbert Y. Meltzer, Helio Elkis, Kimberly Vanover, David M. Weiner, Daniel P. van Kammen: Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day. In: Schizophrenia Research. Band141, Nr.2-3, November 2012, S.144–152, doi:10.1016/j.schres.2012.07.029, PMID 22954754.
Jeffrey Cummings, Stuart Isaacson, Roger Mills, Hilde Williams, Kathy Chi-Burris: Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. In: Lancet (London, England). Band383, Nr.9916, 8. Februar 2014, S.533–540, doi:10.1016/S0140-6736(13)62106-6, PMID 24183563.
Filippo Caraci, Mario Santagati, Giuseppe Caruso, Dario Cannavò, Gian Marco Leggio: New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer’s disease: focus on brexpiprazole and pimavanserin. In: F1000Research. Band9, 8. Juli 2020, S.686, doi:10.12688/f1000research.22662.1.
Pierre N. Tariot, Jeffrey L. Cummings, Maria E. Soto-Martin, Clive Ballard, Deniz Erten-Lyons: Trial of Pimavanserin in Dementia-Related Psychosis. In: New England Journal of Medicine. Band385, Nr.4, 22. Juli 2021, S.309–319, doi:10.1056/NEJMoa2034634.
Clive Ballard, Carol Banister, Zunera Khan, Jeffrey Cummings, George Demos: Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study. In: The Lancet. Neurology. Band17, Nr.3, März 2018, S.213–222, doi:10.1016/S1474-4422(18)30039-5, PMID 29452684.
K Vanover, A Betz, S Weber, F Bibbiani, A Kielaite: A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model. In: Pharmacology Biochemistry and Behavior. Band90, Nr.4, Oktober 2008, S.540–544, doi:10.1016/j.pbb.2008.04.010, PMID 18534670, PMC 2806670 (freier Volltext).
Atheir Abbas, Bryan L. Roth: Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders. In: Expert Opinion on Pharmacotherapy. Band9, Nr.18, Dezember 2008, S.3251–3259, doi:10.1517/14656560802532707, PMID 19040345.
Herbert Y. Meltzer, Helio Elkis, Kimberly Vanover, David M. Weiner, Daniel P. van Kammen: Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day. In: Schizophrenia Research. Band141, Nr.2-3, November 2012, S.144–152, doi:10.1016/j.schres.2012.07.029, PMID 22954754.
Jeffrey Cummings, Stuart Isaacson, Roger Mills, Hilde Williams, Kathy Chi-Burris: Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. In: Lancet (London, England). Band383, Nr.9916, 8. Februar 2014, S.533–540, doi:10.1016/S0140-6736(13)62106-6, PMID 24183563.
Clive Ballard, Carol Banister, Zunera Khan, Jeffrey Cummings, George Demos: Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study. In: The Lancet. Neurology. Band17, Nr.3, März 2018, S.213–222, doi:10.1016/S1474-4422(18)30039-5, PMID 29452684.
